$XBI $127 +1%
Covid Updates
$MRNA +4% UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility. source
$SRNE +11% Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests. source
$MRNA +4% Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine. source
Pipeline Updates
$TVTX -1% Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy. source
$MTCR -2% Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH. source
$SLNO +26% Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a. source
$SCYX -15% SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections. source
$BHC -1% $CLSD +7% BAUSCH HEALTH AND CLEARSIDE BIOMEDICAL ANNOUNCE U.S. FDA FILING ACCEPTANCE FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION). source
$LQDA +6% Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder. source
$LOGC +5% LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia. source
$KZR -9% Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021. source
$KPTI +1% Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma. source
$PLX -16% Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease. source
Financial Updates
$MOR -12% CNST +66% MorphoSys to Acquire Constellation Pharmaceuticals. source
$LYRA +8% THERAPEUTICS AND LIANBIO ANNOUNCE STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LYR-210 IN GREATER CHINA AND OTHER ASIAN MARKETS. source
Posted by DV
Comments